Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironmentPengfei Xu, Chengfei Liu|Journal for ImmunoTherapy of Cancer|2023Cited by 64
Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived modelsPengfei Xu, Chengfei Liu|Pharmacological Research|2023Cited by 20
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancerJoy C. Yang, Chengfei Liu|Oncogene|2023Cited by 18
Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancerPengfei Xu, Chengfei Liu|Nature Communications|2024Cited by 6
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancerBo Chen, Chengfei Liu|Oncogene|2024Cited by 3